Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

Methyltetrahydrofolate Reductase C677T Mutation and 4G/5G Plasminogen Activator Inhibitor-1 Polymorphism in a Child with Deep Vein Thrombosis

The Effects of Regular Aerobic Exercise on the serum levels of Plasminogen Activator Inhibitor-1 and Adiponectin in Obese Girls

Background: The modification of the adipokine levels can be important for the long-term prevention of systemic inflammation related to obesity in children. Objective: The current study aimed to investigate the effects of regular aerobic exercise on the serum levels of plasminogen Activator inhibitor-1(PAI-1) and Adiponectin in obese girls. Methods: This semi experimental research, 14 obese gi...

Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients ‎with Coronary Artery Disease

Background: Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with inhibitory effects on the formation of plasmin from plasminogen by plasminogen activator. Thus, it prevents clot lysis in vessel walls. Several evidences prove the relationship between coronary artery disease and response to fibrinolytic therapy in patients with myocardial infarction with PAI-1 level. Opium addiction i...

Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity

Numerous studies have shown a paradoxical positive correlation between elevated levels of plasminogen activator inhibitior-1 (PAI-1) in tumors and blood of cancer patients with poor clinical outcome, suggesting that PAI-1 could be a therapeutic target. Here we tested two orally bioavailable small molecule inhibitors of PAI-1 (TM5275 and TM5441) for their efficacy in pre-clinical models of cance...

Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist.

Plasminogen activator inhibitor-1 (PAI-1), a serpin, is the physiological inhibitor of tissue-type and urokinase-type plasminogen activators and thus also an inhibitor of fibrinolysis and tissue remodeling. It is a potential therapeutic target in many pathological conditions, including thrombosis and cancer. Several types of PAI-1 antagonist have been developed, but the structural basis for the...